Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Azatiq

(Iberdomide)

Phase 3Small molecule

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Iberdomide is used to treat multiple myeloma, a type of blood cancer, often in combination with other medications. It works by helping the immune system fight cancer cells and preventing the cancer from growing.[1] Azatiq is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]

Azatiq is one of 99 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.

8

Indications

37

Total Trials

30

Active Trials

98

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

7

Patents

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Non-Hodgkin LymphomaActive, not recruiting

DexamethasoneRecruiting

MRDActive, not recruiting

Recurrent Multiple MyelomaRecruiting

Newly Diagnosed Multiple MyelomaRecruiting

Recurrent GanglioneuroblastomaNot yet recruiting

Newly Diagnosed PatientsNot yet recruiting

Multiple MyelomaPhase 3

Active, not recruiting

Non-Hodgkin LymphomaPhase 1

Active, not recruiting

DexamethasonePreclinical

Recruiting

MRDPhase 2

Active, not recruiting

Recurrent Multiple MyelomaPhase 1

Recruiting

Newly Diagnosed Multiple MyelomaPhase 3

Recruiting

Recurrent GanglioneuroblastomaPreclinical

Not yet recruiting

Newly Diagnosed PatientsPhase 2

Not yet recruiting

Competition

Competitive Landscape

259 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Empliciti

Bristol-Myers Squibb

Fludara

Venclexta

Biaxin

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Elranatamab

Cytosar

Sylvant

RRECORDATI GROUP

Linvoseltamab

Daratumumab SC

Johnson & Johnson

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Multiple Myeloma

NCT05560399

Phase 1Recruiting

Recurrent Multiple Myeloma

NCT06465316

Q2 2027

Phase 2Active, not recruiting

Multiple Myeloma

NCT05354557

Q4 2027

Phase 2Active, not recruiting

Multiple Myeloma

NCT04564703

Q3 2028

PreclinicalRecruiting

Multiple Myeloma

NCT05583617

Phase 1Recruiting

Multiple Myeloma

NCT06121843

Clinical

Trials by Indication[1]

Multiple Myeloma22 trials

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT05560399·7 enrolled

Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

Active, not recruiting·UUniversity of Nebraska·Phase 2·NCT05177536·40 enrolled

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT06896916·135 enrolled

Show 19 more trials

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Active, not recruiting·NNantes University Hospital·Phase 2·NCT04998786·75 enrolled

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04975997·864 enrolled

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Terminated·IiTeos Therapeutics·Phase 1·NCT05289492·16 enrolled

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Recruiting·—·Phase 1·NCT06348108·32 enrolled

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting·—·Phase 2·NCT05896228·30 enrolled

Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients

Suspended·NNational Cancer Institute (NCI)·Phase 2·NCT06179888·84 enrolled

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT06892522·602 enrolled

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (NDMM)

Recruiting·DDana-Farber Cancer Institute·Phase 3·NCT07624513·720 enrolled

A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients With Multiple Myeloma

Recruiting· Roche logo

Roche·Preclinical·NCT05583617·200 enrolled

Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients With Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation or After Salvage Autologous Hematopoietic Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05354557·16 enrolled

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT05827016·1,230 enrolled

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT06215118·100 enrolled

A Single Arm, Response-adapted, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone (IberBd) With Isatuximab Added on Demand for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial

Recruiting·CCanadian Myeloma Research Group·Phase 2·NCT05272826·75 enrolled

A Randomized Phase III Trial Assessing Iberdomide Versus Iberdomide Plus Isatuximab Maintenance Therapy Post Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·UUniversity of Heidelberg Medical Center·Phase 3·NCT06216158·411 enrolled

Feasibility Study of Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Not yet recruiting·SShambavi Richard·Phase 1·NCT07727668·22 enrolled

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06121843·187 enrolled

Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients

Active, not recruiting·SStichting European Myeloma Network·Phase 2·NCT04564703·160 enrolled

A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma

Suspended·HHackensack Meridian Health·Preclinical·NCT05199311·66 enrolled

IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma

Recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT06107738·60 enrolled

Recurrent Multiple Myeloma3 trials

A Phase 1b Trial of Teclistamab in Combination With Iberdomide for Relapsed/Refractory Multiple Myeloma

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06465316·26 enrolled

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma

Suspended·AAlliance for Clinical Trials in Oncology·Preclinical·NCT06232044·88 enrolled

Phase 1/2 Trial of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma

Recruiting·MMayo Clinic·Preclinical·NCT06785415·37 enrolled

Newly Diagnosed Multiple Myeloma2 trials

A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant

Not yet recruiting·DDana-Farber Cancer Institute·Preclinical·NCT07601100·88 enrolled

GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D

Recruiting·PPETHEMA Foundation·Phase 3·NCT05558319·480 enrolled

Adult1 trial

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT05899738·32 enrolled

MRD1 trial

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

Active, not recruiting·UUniversity of Alabama at Birmingham·Phase 1/2·NCT05434689·80 enrolled

8 more indications

Impairment1 trial

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04933747·26 enrolled

ESS1 trial

Expanded Access for Iberdomide

Available· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07434960

Newly Diagnosed Patients1 trial

Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Not yet recruiting·PPETHEMA Foundation·Phase 2·NCT05527340·140 enrolled

Recurrent Ganglioneuroblastoma1 trial

Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT07437963·76 enrolled

Myeloma1 trial

A Phase I Study of Elotuzumab and Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Recruiting·OOmar Nadeem, MD·Phase 1·NCT06518551·24 enrolled

Smouldering Myeloma1 trial

Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Recruiting·UUniversity College, London·Phase 2·NCT06762769·63 enrolled

Plasma Cell Myeloma1 trial

Phase 1/2 Trial of Iberdomide in Combination With Daratumumab, BortEzomib and DexamethAsone in Patients With Newly Diagnosed Multiple MyeLoma (IDEAL)

Active, not recruiting·MMayo Clinic·Preclinical·NCT05392946·49 enrolled

Non-Hodgkin Lymphoma1 trial

A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma

Active, not recruiting· Roche logo

Roche·Phase 1·NCT05169515·121 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 13, 2026

ZENBEXUS

NDA NDA221075

Sources

References

[1]
ClinicalTrials.gov — 37 trial records for Iberdomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iberdomide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iberdomide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA221075). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Azatiq. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CRL4(CRBN) E3 Ubiquitin Ligase Modulator[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Patent Landscape[5]

Patent Cliff

Feb 10, 2031

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9828361Feb 10, 2031

8518972Jun 5, 2031

9629849Aug 8, 2033

9221788Sep 25, 2033

RE50917Oct 7, 2034

2 more patents

RE49647Oct 7, 2034

11529339Sep 30, 2039

Related News